Cargando…
Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways
The mechanisms by which myelodysplastic syndrome (MDS) cells resist the effects of hypomethylating agents (HMA) are currently the subject of intensive research. A better understanding of mechanisms by which the MDS cell becomes to tolerate HMA and progresses to acute myeloid leukemia (AML) requires...
Autores principales: | Minařík, Lubomír, Pimková, Kristýna, Kokavec, Juraj, Schaffartziková, Adéla, Vellieux, Fréderic, Kulvait, Vojtěch, Daumová, Lenka, Dusilková, Nina, Jonášová, Anna, Vargová, Karina Savvulidi, Králová Viziová, Petra, Sedláček, Radislav, Zemanová, Zuzana, Stopka, Tomáš |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774143/ https://www.ncbi.nlm.nih.gov/pubmed/35053339 http://dx.doi.org/10.3390/cells11020223 |
Ejemplares similares
-
P692: THE KEAP1-NRF2 REDOX PATHWAY IS OF CENTRAL IMPORTANCE DURING 5-AZACYTIDINE THERAPY AND THE DEVELOPMENT OF RESISTANCE VIA A SPECIFIC SET OF PROTEIN OXIDATIVE MODIFICATIONS
por: Pimková, Kristýna, et al.
Publicado: (2023) -
Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders
por: Polgarova, Kamila, et al.
Publicado: (2017) -
G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
por: Stopka, Tomáš, et al.
Publicado: (2022) -
Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation
por: Pospisil, Vit, et al.
Publicado: (2011) -
PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)